1. Home
  2. CING vs HBIO Comparison

CING vs HBIO Comparison

Compare CING & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CING
  • HBIO
  • Stock Information
  • Founded
  • CING 2012
  • HBIO 1901
  • Country
  • CING United States
  • HBIO United States
  • Employees
  • CING N/A
  • HBIO N/A
  • Industry
  • CING Biotechnology: Pharmaceutical Preparations
  • HBIO Biotechnology: Laboratory Analytical Instruments
  • Sector
  • CING Health Care
  • HBIO Industrials
  • Exchange
  • CING Nasdaq
  • HBIO Nasdaq
  • Market Cap
  • CING 16.2M
  • HBIO 15.3M
  • IPO Year
  • CING 2021
  • HBIO 2000
  • Fundamental
  • Price
  • CING $4.36
  • HBIO $0.41
  • Analyst Decision
  • CING Strong Buy
  • HBIO Buy
  • Analyst Count
  • CING 4
  • HBIO 2
  • Target Price
  • CING $30.67
  • HBIO $3.00
  • AVG Volume (30 Days)
  • CING 250.6K
  • HBIO 34.9M
  • Earning Date
  • CING 05-08-2025
  • HBIO 05-12-2025
  • Dividend Yield
  • CING N/A
  • HBIO N/A
  • EPS Growth
  • CING N/A
  • HBIO N/A
  • EPS
  • CING N/A
  • HBIO N/A
  • Revenue
  • CING N/A
  • HBIO $91,397,000.00
  • Revenue This Year
  • CING N/A
  • HBIO N/A
  • Revenue Next Year
  • CING N/A
  • HBIO $9.75
  • P/E Ratio
  • CING N/A
  • HBIO N/A
  • Revenue Growth
  • CING N/A
  • HBIO N/A
  • 52 Week Low
  • CING $1.80
  • HBIO $0.28
  • 52 Week High
  • CING $20.83
  • HBIO $3.60
  • Technical
  • Relative Strength Index (RSI)
  • CING 61.94
  • HBIO 50.65
  • Support Level
  • CING $3.81
  • HBIO $0.37
  • Resistance Level
  • CING $4.09
  • HBIO $0.44
  • Average True Range (ATR)
  • CING 0.26
  • HBIO 0.10
  • MACD
  • CING 0.07
  • HBIO 0.01
  • Stochastic Oscillator
  • CING 96.43
  • HBIO 19.24

About CING Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.

About HBIO Harvard Bioscience Inc.

Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States.

Share on Social Networks: